Simmunome Inc.
2 known investors
Simmunome develops AI-powered disease simulation software for drug development, combining mechanistic modeling with machine learning to predict target efficacy and identify patient responders in clinical trials. The SaaS platform serves biotech and pharmaceutical companies across oncology, neurology, and metabolic disease indications.